PL3733673T3 - Pochodna oksyfluoropiperydyny jako inhibitor kinazy - Google Patents

Pochodna oksyfluoropiperydyny jako inhibitor kinazy

Info

Publication number
PL3733673T3
PL3733673T3 PL18896304.5T PL18896304T PL3733673T3 PL 3733673 T3 PL3733673 T3 PL 3733673T3 PL 18896304 T PL18896304 T PL 18896304T PL 3733673 T3 PL3733673 T3 PL 3733673T3
Authority
PL
Poland
Prior art keywords
oxy
kinase inhibitor
fluoropiperidine
derivative
fluoropiperidine derivative
Prior art date
Application number
PL18896304.5T
Other languages
English (en)
Inventor
In Woo Kim
Sun Ah Jun
Nam Youn Kim
Jun Hee Lee
Original Assignee
Daewoong Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewoong Pharmaceutical Co., Ltd. filed Critical Daewoong Pharmaceutical Co., Ltd.
Publication of PL3733673T3 publication Critical patent/PL3733673T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL18896304.5T 2017-12-28 2018-12-28 Pochodna oksyfluoropiperydyny jako inhibitor kinazy PL3733673T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170183061 2017-12-28
PCT/KR2018/016814 WO2019132562A1 (ko) 2017-12-28 2018-12-28 카이네이즈 저해제로서의 옥시-플루오로피페리딘 유도체

Publications (1)

Publication Number Publication Date
PL3733673T3 true PL3733673T3 (pl) 2022-09-26

Family

ID=67067864

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18896304.5T PL3733673T3 (pl) 2017-12-28 2018-12-28 Pochodna oksyfluoropiperydyny jako inhibitor kinazy

Country Status (32)

Country Link
US (1) US11339167B2 (pl)
EP (1) EP3733673B1 (pl)
JP (1) JP6995428B2 (pl)
KR (2) KR102318929B1 (pl)
CN (1) CN111527091B (pl)
AU (1) AU2018394997B2 (pl)
BR (1) BR112020013141B1 (pl)
CA (1) CA3084962C (pl)
CL (1) CL2020001752A1 (pl)
CO (1) CO2020007162A2 (pl)
DO (1) DOP2020000112A (pl)
EC (1) ECSP20035590A (pl)
ES (1) ES2922633T3 (pl)
HR (1) HRP20221043T1 (pl)
HU (1) HUE059580T2 (pl)
IL (1) IL275207B (pl)
LT (1) LT3733673T (pl)
MA (1) MA51431B1 (pl)
MX (1) MX2020006799A (pl)
MY (1) MY194468A (pl)
NZ (1) NZ764644A (pl)
PE (1) PE20201146A1 (pl)
PH (1) PH12020551013A1 (pl)
PL (1) PL3733673T3 (pl)
PT (1) PT3733673T (pl)
RS (1) RS63515B1 (pl)
RU (1) RU2758370C1 (pl)
SA (1) SA520412335B1 (pl)
SG (1) SG11202004917UA (pl)
SI (1) SI3733673T1 (pl)
TN (1) TN2020000082A1 (pl)
WO (1) WO2019132562A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3652169A1 (en) 2017-08-01 2020-05-20 Theravance Biopharma R&D IP, LLC Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors
PL3733673T3 (pl) * 2017-12-28 2022-09-26 Daewoong Pharmaceutical Co., Ltd. Pochodna oksyfluoropiperydyny jako inhibitor kinazy
KR102577242B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
KR102328682B1 (ko) 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
JP2022518741A (ja) 2019-01-23 2022-03-16 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー JAKキナーゼ阻害剤としてのイミダゾ[1,5-a]ピリジン、1,2,4-トリアゾロ[4,3-a]ピリジンおよびイミダゾ[1,5-a]ピラジン
WO2021108803A1 (en) 2019-11-26 2021-06-03 Theravance Biopharma R&D Ip, Llc Fused pyrimidine pyridinone compounds as jak inhibitors
CN115023428B (zh) * 2020-01-21 2025-04-08 江苏先声药业有限公司 嘧啶并吡咯类化合物
CN115244055B (zh) * 2020-01-21 2024-09-03 江苏先声药业有限公司 嘧啶并五元环类衍生物及其应用
WO2022062601A1 (zh) * 2020-09-22 2022-03-31 江苏先声药业有限公司 嘧啶并吡咯类化合物
CN114315838B (zh) * 2020-09-30 2024-09-03 江苏先声药业有限公司 嘧啶并吡咯类化合物
WO2023165562A1 (zh) * 2022-03-02 2023-09-07 南京明德新药研发有限公司 含氮杂环类化合物及其应用
CN116768908B (zh) * 2022-03-10 2025-11-18 石家庄迪斯凯威医药科技有限公司 一种含n多环化合物及其制备方法与用途
WO2025121903A1 (ko) * 2023-12-05 2025-06-12 주식회사 대웅제약 1-((3s,4r)-3-((2-((1-에틸-1h-피라졸-4-일)아미노)-7h-피롤로[2,3-d]피리미딘-4-일)옥시)-4-플루오로피페리딘-1-일)프로프-2-엔-1-온의 타타르산염, 이의 결정형 및 이의 제조 방법
WO2025121900A1 (ko) * 2023-12-05 2025-06-12 주식회사 대웅제약 1-((3s,4r)-3-((2-((1-에틸-1h-피라졸-4-일)아미노)-7h-피롤로[2,3-d]피리미딘-4-일)옥시)-4-플루오로피페리딘-1-일)프로프-2-엔-1-온의 인산염, 이의 결정형 및 이의 제조 방법
TWI909862B (zh) * 2023-12-05 2025-12-21 南韓商大熊製藥股份有限公司 1-((3S,4R)-3-((2-((1-乙基-1H-吡唑-4-基)胺基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧基)-4-氟哌啶-1-基)丙-2-烯-1-酮的製備方法、及其中間體化合物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
US7705004B2 (en) * 2007-08-17 2010-04-27 Portola Pharmaceuticals, Inc. Protein kinase inhibitors
JP2011518219A (ja) * 2008-04-22 2011-06-23 ポートラ ファーマシューティカルズ, インコーポレイテッド タンパク質キナーゼの阻害剤
CA2730930C (en) 2008-07-16 2015-01-13 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
JP5918693B2 (ja) * 2009-05-05 2016-05-18 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Egfr阻害剤及び疾患の治療方法
CA2803056C (en) 2010-06-23 2017-05-16 Hanmi Science Co., Ltd. Fused pyrimidine derivatives for inhibition of tyrosine kinase activity
ES2575710T3 (es) * 2011-09-22 2016-06-30 Pfizer Inc Derivados de pirrolopirimidina y purina
ES2733576T3 (es) * 2012-08-06 2019-12-02 Acea Therapeutics Inc Nuevos compuestos de pirrolopirimidina como inhibidores de proteína cinasas
MX2015009209A (es) 2013-01-16 2016-03-17 Signal Pharm Llc Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y metodos de tratamiento con los mismos.
WO2014135473A1 (en) 2013-03-05 2014-09-12 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
US9840517B2 (en) * 2013-09-18 2017-12-12 Beijing Hanmi Pharmaceutical Co., Ltd. Compound inhibiting activities of BTK and/or JAK3 kinases
ES2654051T3 (es) 2013-12-05 2018-02-12 Pfizer Inc. Pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinil acrilamidas
WO2016000615A1 (en) * 2014-07-02 2016-01-07 Sunshine Lake Pharma Co., Ltd. Heteroaryl compounds and pharmaceutical applications thereof
CN105732637B (zh) 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
CN108934162A (zh) 2015-12-16 2018-12-04 南方研究所 吡咯并嘧啶化合物、作为激酶lrrk2抑制剂的用途及其制备方法
KR102329162B1 (ko) * 2016-06-30 2021-11-22 주식회사 대웅제약 카이네이즈 저해제로서의 피라졸로피리미딘 유도체
KR102032418B1 (ko) 2017-06-15 2019-10-16 한국화학연구원 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물
PL3733673T3 (pl) * 2017-12-28 2022-09-26 Daewoong Pharmaceutical Co., Ltd. Pochodna oksyfluoropiperydyny jako inhibitor kinazy
KR102577242B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
KR102577241B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체

Also Published As

Publication number Publication date
AU2018394997B2 (en) 2021-02-04
SA520412335B1 (ar) 2022-09-19
KR20190080803A (ko) 2019-07-08
EP3733673A4 (en) 2021-06-09
AU2018394997A1 (en) 2020-06-11
IL275207A (en) 2020-07-30
US20200308177A1 (en) 2020-10-01
RU2758370C1 (ru) 2021-10-28
ECSP20035590A (es) 2020-07-31
ES2922633T3 (es) 2022-09-19
EP3733673B1 (en) 2022-06-29
SG11202004917UA (en) 2020-06-29
LT3733673T (lt) 2022-08-10
MA51431A (fr) 2021-04-07
KR102318929B1 (ko) 2021-10-28
KR102592083B1 (ko) 2023-10-20
PT3733673T (pt) 2022-07-18
NZ764644A (en) 2023-06-30
JP6995428B2 (ja) 2022-01-14
HUE059580T2 (hu) 2022-11-28
CO2020007162A2 (es) 2020-06-19
IL275207B (en) 2022-09-01
TN2020000082A1 (en) 2022-01-06
MY194468A (en) 2022-11-30
CN111527091A (zh) 2020-08-11
KR20210062618A (ko) 2021-05-31
MX2020006799A (es) 2020-09-03
BR112020013141B1 (pt) 2022-03-15
CA3084962A1 (en) 2019-07-04
HRP20221043T1 (hr) 2022-11-11
SI3733673T1 (sl) 2022-09-30
CN111527091B (zh) 2023-03-28
US11339167B2 (en) 2022-05-24
BR112020013141A2 (pt) 2021-02-23
CA3084962C (en) 2022-08-09
WO2019132562A1 (ko) 2019-07-04
EP3733673A1 (en) 2020-11-04
MA51431B1 (fr) 2022-08-31
JP2021506818A (ja) 2021-02-22
DOP2020000112A (es) 2020-08-31
PH12020551013A1 (en) 2021-08-16
CL2020001752A1 (es) 2020-11-27
RS63515B1 (sr) 2022-09-30
PE20201146A1 (es) 2020-10-26

Similar Documents

Publication Publication Date Title
HUS2400003I1 (hu) Kináz inhibitorként alkalmas vegyületek
IL275207A (en) An oxyfluoropiperidine derivative as a kinase inhibitor
IL268614A (en) Aminotriazolopyridines as kinase inhibitors
SG11202004918XA (en) Amino-fluoropiperidine derivative as kinase inhibitor
ZA201808431B (en) Pyrazolopyrimidine derivatives as kinase inhibitor
IL276269A (en) Aminopyrrolotriazines as kinase inhibitors
IL274207A (en) Aminoimidazopyridazines as kinase inhibitors
SG11202004916YA (en) Amino-methyl piperidine derivative as kinase inhibitor
IL269063B (en) Pyrimidopyrimidinones used as wee-1 kinase inhibitors
IL269144A (en) Pyrrolotriazine derivatives as kinase inhibitors
GB201613945D0 (en) Compounds useful as kinase inhibitors
GB201708502D0 (en) Inhibitor compounds
HK1261567A1 (en) Tank-binding kinase inhibitor compounds
GB201522245D0 (en) Compounds useful as kinase inhibitors